Kathleen M Mortimer1, Dorothee B Bartels2, Nadine Hartmann3, Jorge Capapey4, Jing Yang5, Robert Gately1, Cheryl Enger6. 1. Optum Epidemiology, Boston, Massachusetts, USA. 2. Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany. 3. Boehringer Ingelheim International GmbH, Ingelheim, Germany. 4. Alnylam Pharmaceuticals, Madrid, Spain. 5. Optum Epidemiology, Ann Arbor, Michigan, USA. 6. Optum Epidemiology, Ann Arbor, Michigan, USA, cheryl.enger@optum.com.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a life-threatening interstitial lung disease (ILD). Characterizing health outcomes of IPF patients is challenging due to disease rarity. OBJECTIVE: This study aimed to identify the burden of disease in patients newly diagnosed with IPF. METHODS: Patients with ≥1 claim with an IPF diagnosis were identified from a United States healthcare insurer's database (2000-2013). Patients with other known causes of ILD or aged <40 years were excluded. Subgroups were compared based on the 2011 change in International Classification of Diseases, 9th Revision (ICD-9) definition of IPF and occurrence of IPF testing. The prevalence and incidence of preselected health conditions of clinical interest were estimated. RESULTS: Median age of newly diagnosed patients (n = 7,298) was 62 years (54.0% male). Restricting to patients with IPF diagnostic testing did not substantially affect cohort characteristics, nor did ICD-9 IPF coding change. Mean follow-up was 1.7 years; 16.8% of patients died; and a substantial proportion of patients were censored due to end of health plan enrollment (50.7%) and other causes of ILD (19.6%). The incidence of pulmonary hypertension, lung cancer, and claims-based algorithm proxy for acute respiratory worsening of unknown cause was 22.5, 17.6, and 12.6 per 1,000 person-years, respectively. CONCLUSIONS: Patients with IPF had a high disease burden with a variety of health outcomes observed, including a high rate of mortality. Database censoring due to changes in enrollment or other ILD diagnoses limited follow-up. Altering cohort entry definitions, including IPF testing or ICD-9 IPF coding change, had little impact on cohort baseline characteristics.
BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a life-threatening interstitial lung disease (ILD). Characterizing health outcomes of IPFpatients is challenging due to disease rarity. OBJECTIVE: This study aimed to identify the burden of disease in patients newly diagnosed with IPF. METHODS:Patients with ≥1 claim with an IPF diagnosis were identified from a United States healthcare insurer's database (2000-2013). Patients with other known causes of ILD or aged <40 years were excluded. Subgroups were compared based on the 2011 change in International Classification of Diseases, 9th Revision (ICD-9) definition of IPF and occurrence of IPF testing. The prevalence and incidence of preselected health conditions of clinical interest were estimated. RESULTS: Median age of newly diagnosed patients (n = 7,298) was 62 years (54.0% male). Restricting to patients with IPF diagnostic testing did not substantially affect cohort characteristics, nor did ICD-9 IPF coding change. Mean follow-up was 1.7 years; 16.8% of patients died; and a substantial proportion of patients were censored due to end of health plan enrollment (50.7%) and other causes of ILD (19.6%). The incidence of pulmonary hypertension, lung cancer, and claims-based algorithm proxy for acute respiratory worsening of unknown cause was 22.5, 17.6, and 12.6 per 1,000 person-years, respectively. CONCLUSIONS:Patients with IPF had a high disease burden with a variety of health outcomes observed, including a high rate of mortality. Database censoring due to changes in enrollment or other ILD diagnoses limited follow-up. Altering cohort entry definitions, including IPF testing or ICD-9 IPF coding change, had little impact on cohort baseline characteristics.
Authors: Harold R Collard; Bethany B Moore; Kevin R Flaherty; Kevin K Brown; Robert J Kaner; Talmadge E King; Joseph A Lasky; James E Loyd; Imre Noth; Mitchell A Olman; Ganesh Raghu; Jesse Roman; Jay H Ryu; David A Zisman; Gary W Hunninghake; Thomas V Colby; Jim J Egan; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Yasuhiro Kondoh; David A Lynch; Joachim Müller-Quernheim; Jeffrey L Myers; Andrew G Nicholson; Moisés Selman; Galen B Toews; Athol U Wells; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2007-06-21 Impact factor: 21.405
Authors: Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann Journal: Am J Respir Crit Care Med Date: 2011-03-15 Impact factor: 21.405
Authors: Seo Young Kim; Daniel H Solomon; Jun Liu; Chun-Lan Chang; Gregory W Daniel; Sebastian Schneeweiss Journal: Pharmacoepidemiol Drug Saf Date: 2011-05-12 Impact factor: 2.890
Authors: Noam Y Kirson; Howard G Birnbaum; Jasmina I Ivanova; Tracy Waldman; Vijay Joish; Todd Williamson Journal: Curr Med Res Opin Date: 2011-07-27 Impact factor: 2.580
Authors: Hude Quan; Nadia Khan; Brenda R Hemmelgarn; Karen Tu; Guanmin Chen; Norm Campbell; Michael D Hill; William A Ghali; Finlay A McAlister Journal: Hypertension Date: 2009-10-26 Impact factor: 10.190
Authors: Dmytro Onishchenko; Robert J Marlowe; Che G Ngufor; Louis J Faust; Andrew H Limper; Gary M Hunninghake; Fernando J Martinez; Ishanu Chattopadhyay Journal: Nat Med Date: 2022-09-29 Impact factor: 87.241